N

Nanjing Vazyme Biotech Co Ltd
SSE:688105

Watchlist Manager
Nanjing Vazyme Biotech Co Ltd
SSE:688105
Watchlist
Price: 23.13 CNY -2.16% Market Closed
Market Cap: 9.3B CNY
Have any thoughts about
Nanjing Vazyme Biotech Co Ltd?
Write Note

Cash Flow Statement

Cash Flow Statement
Nanjing Vazyme Biotech Co Ltd

Rotate your device to view
Cash Flow Statement
Currency: CNY
Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024
Operating Cash Flow
Cash Taxes Paid
(242)
(182)
(176)
(172)
(180)
(186)
(147)
(205)
(127)
(86)
(100)
(9)
(59)
(57)
Change in Working Capital
(634)
(537)
(649)
(823)
(889)
(1 018)
(1 194)
(1 293)
(1 329)
(1 263)
(1 043)
(886)
(817)
(811)
Cash from Operating Activities
1 112
N/A
583
-48%
617
+6%
453
-27%
440
-3%
445
+1%
735
+65%
553
-25%
649
+17%
589
-9%
153
-74%
181
+18%
34
-81%
72
+111%
Investing Cash Flow
Capital Expenditures
(297)
(268)
(262)
(576)
(731)
(812)
(963)
(681)
(523)
(437)
(233)
(168)
(101)
(65)
Other Items
(895)
(328)
(1 166)
(1 303)
(1 109)
(896)
10
(121)
273
(695)
(668)
299
(283)
268
Cash from Investing Activities
(1 192)
N/A
(596)
+50%
(1 428)
-139%
(1 879)
-32%
(1 840)
+2%
(1 708)
+7%
(952)
+44%
(803)
+16%
(250)
+69%
(1 132)
-353%
(901)
+20%
131
N/A
(384)
N/A
203
N/A
Financing Cash Flow
Net Issuance of Debt
(51)
(25)
(40)
0
(31)
185
216
942
1 096
962
822
(174)
(735)
(836)
Cash Paid for Dividends
0
0
(4)
0
0
(126)
(132)
(135)
(647)
(534)
(533)
(538)
(36)
(62)
Other
292
(7)
2 114
0
1 997
0
(4)
0
(19)
(19)
(39)
(96)
(125)
(128)
Cash from Financing Activities
241
N/A
(32)
N/A
2 070
N/A
0
N/A
1 961
N/A
2 177
+11%
79
-96%
802
+915%
551
-31%
409
-26%
250
-39%
(808)
N/A
(896)
-11%
(1 026)
-14%
Change in Cash
Effect of Foreign Exchange Rates
(5)
(4)
(2)
(4)
(1)
(2)
5
7
8
8
1
1
(3)
(1)
Net Change in Cash
156
N/A
(49)
N/A
1 256
N/A
649
-48%
559
-14%
912
+63%
(133)
N/A
560
N/A
958
+71%
(126)
N/A
(496)
-294%
(495)
+0%
(1 250)
-152%
(752)
+40%
Free Cash Flow
Free Cash Flow
814
N/A
315
-61%
355
+13%
(123)
N/A
(291)
-137%
(367)
-26%
(228)
+38%
(128)
+44%
126
N/A
152
+20%
(80)
N/A
12
N/A
(67)
N/A
7
N/A

See Also

Discover More